vs
Side-by-side financial comparison of Cencora (COR) and Marqeta, Inc. (MQ). Click either name above to swap in a different company.
Marqeta, Inc. is the larger business by last-quarter revenue ($165.8B vs $78.4B, roughly 2.1× Cencora). Cencora runs the higher net margin — 2.1% vs 0.0%, a 2.1% gap on every dollar of revenue. On growth, Marqeta, Inc. posted the faster year-over-year revenue change (19.0% vs 3.8%). Over the past eight quarters, Marqeta, Inc.'s revenue compounded faster (3538.0% CAGR vs -0.4%).
Cencora, Inc., formerly known as AmerisourceBergen, is an American drug wholesale and distribution company and a contract research organization, that was formed by the merger of Bergen Brunswig and AmeriSource in 2001. It was renamed to Cencora in 2023. Cencora is one of the largest pharmaceutical companies in the world and distributes generic pharmaceuticals, over-the-counter healthcare products, as well as home healthcare supplies and equipment.
Marqeta, Inc. operates a cloud-native open API platform for modern card issuing and digital payment processing. Its solutions empower fintech startups, large retailers, and enterprise clients to launch customized physical and virtual payment cards, as well as embedded finance products across global consumer and commercial markets.
COR vs MQ — Head-to-Head
Income Statement — Q3 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $78.4B | $165.8B |
| Net Profit | $1.6B | $7.8M |
| Gross Margin | 4.6% | 0.1% |
| Operating Margin | 1.5% | 99.9% |
| Net Margin | 2.1% | 0.0% |
| Revenue YoY | 3.8% | 19.0% |
| Net Profit YoY | 2.1% | 662.0% |
| EPS (diluted) | $8.40 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 26 | $78.4B | — | ||
| Q1 26 | $85.9B | $165.8B | ||
| Q4 25 | $85.9B | $172.1M | ||
| Q3 25 | $83.7B | $163.3M | ||
| Q2 25 | $80.7B | $150.4M | ||
| Q1 25 | $75.5B | $139.1M | ||
| Q4 24 | $81.5B | $135.8M | ||
| Q3 24 | $79.1B | $128.0M |
| Q2 26 | $1.6B | — | ||
| Q1 26 | $566.1M | $7.8M | ||
| Q4 25 | $559.6M | — | ||
| Q3 25 | $-339.7M | $-3.6M | ||
| Q2 25 | $687.4M | $-647.0K | ||
| Q1 25 | $717.9M | $-8.3M | ||
| Q4 24 | $488.6M | — | ||
| Q3 24 | $3.4M | $-28.6M |
| Q2 26 | 4.6% | — | ||
| Q1 26 | 3.6% | 0.1% | ||
| Q4 25 | 3.6% | 69.7% | ||
| Q3 25 | 3.5% | 70.1% | ||
| Q2 25 | 3.6% | 69.2% | ||
| Q1 25 | 4.1% | 71.0% | ||
| Q4 24 | 3.1% | 72.3% | ||
| Q3 24 | 3.2% | 70.4% |
| Q2 26 | 1.5% | — | ||
| Q1 26 | 0.9% | 99.9% | ||
| Q4 25 | 0.9% | -4.8% | ||
| Q3 25 | 0.0% | -6.4% | ||
| Q2 25 | 1.1% | -6.1% | ||
| Q1 25 | 1.4% | -13.3% | ||
| Q4 24 | 0.9% | -27.6% | ||
| Q3 24 | 0.2% | -33.0% |
| Q2 26 | 2.1% | — | ||
| Q1 26 | 0.7% | 0.0% | ||
| Q4 25 | 0.7% | — | ||
| Q3 25 | -0.4% | -2.2% | ||
| Q2 25 | 0.9% | -0.4% | ||
| Q1 25 | 1.0% | -5.9% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | -22.4% |
| Q2 26 | $8.40 | — | ||
| Q1 26 | $2.87 | $0.02 | ||
| Q4 25 | $2.87 | — | ||
| Q3 25 | $-1.74 | — | ||
| Q2 25 | $3.52 | — | ||
| Q1 25 | $3.68 | — | ||
| Q4 24 | $2.50 | — | ||
| Q3 24 | $0.04 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.2B | $712.1M |
| Total DebtLower is stronger | $12.4B | — |
| Stockholders' EquityBook value | $3.6B | $742.3M |
| Total Assets | $81.7B | $1.5B |
| Debt / EquityLower = less leverage | 3.45× | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 26 | $2.2B | — | ||
| Q1 26 | $1.8B | $712.1M | ||
| Q4 25 | $1.8B | $709.4M | ||
| Q3 25 | $4.4B | $747.2M | ||
| Q2 25 | $2.2B | $732.7M | ||
| Q1 25 | $2.0B | $830.9M | ||
| Q4 24 | $3.2B | $923.0M | ||
| Q3 24 | $3.1B | $886.4M |
| Q2 26 | $12.4B | — | ||
| Q1 26 | $7.9B | — | ||
| Q4 25 | $7.9B | — | ||
| Q3 25 | $7.7B | — | ||
| Q2 25 | $8.2B | — | ||
| Q1 25 | $7.9B | — | ||
| Q4 24 | $8.1B | — | ||
| Q3 24 | $4.4B | — |
| Q2 26 | $3.6B | — | ||
| Q1 26 | $2.1B | $742.3M | ||
| Q4 25 | $1.9B | $762.0M | ||
| Q3 25 | $1.5B | $839.2M | ||
| Q2 25 | $2.0B | $843.4M | ||
| Q1 25 | $1.0B | $987.3M | ||
| Q4 24 | $226.6M | $1.1B | ||
| Q3 24 | $645.9M | $1.1B |
| Q2 26 | $81.7B | — | ||
| Q1 26 | $78.4B | $1.5B | ||
| Q4 25 | $78.4B | $1.5B | ||
| Q3 25 | $76.6B | $1.5B | ||
| Q2 25 | $74.0B | $1.2B | ||
| Q1 25 | $71.2B | $1.3B | ||
| Q4 24 | $69.1B | $1.5B | ||
| Q3 24 | $67.1B | $1.4B |
| Q2 26 | 3.45× | — | ||
| Q1 26 | 3.78× | — | ||
| Q4 25 | 4.15× | — | ||
| Q3 25 | 5.08× | — | ||
| Q2 25 | 4.16× | — | ||
| Q1 25 | 7.76× | — | ||
| Q4 24 | 35.96× | — | ||
| Q3 24 | 6.79× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
COR
| U.S. Healthcare Solutions | $68.8B | 88% |
| International Healthcare Solutions | $7.6B | 10% |
| Other | $2.0B | 3% |
MQ
Segment breakdown not available.
